
HDFC Pharma and Healthcare Fund - Regular (G)
Equity · Sectoral
28.41%
Last 1 year
- Exit Load
- 1.00%
- Expense Ratio
- 2.12%
- Min. AmountMin. SIP Amount
- ₹100
- Min. Lump SumMin. Lump sum
- ₹100
Historical View
Return Calculator
- Invested Amount
- ₹9,00,000
- Calculated AmountCurrent Value
- ₹14,40,737
- IRR
- 28.893%
- Absolute Gain
- +₹5,40,737 (+60.1%)
Returns & Rankings
Category: Equity Sectoral


63 ProductsEquity Sectoral Funds


63 ProductsWealthy Score
Return Score rates how well the fund has rewarded investors over time, comparing its returns across periods with other funds in its category.
- 1Y Returns
- 28.4%
- 3Y Returns
- 28.9%
- Alpha
- 21.02
Holding Analysis
Equity/Debt/Cash Split
- Equity98.8%
- Debt1.2%
Market Cap Weightage
- Large Cap34.2%
- Mid Cap32.4%
- Small Cap32.1%
- Others1.2%
Sector allocation
- Healthcare98.8%
- Debt1.2%
Top 10 HoldingsTop Holdings
| Stocks | Sector | Percentage |
|---|---|---|
| Divi's Lab. | Pharmaceuticals | 9.44% |
| Sun Pharma.Inds. | Pharmaceuticals | 7.74% |
| Dr Reddy's Labs | Pharmaceuticals | 6.66% |
| Apollo Hospitals | Healthcare | 5.19% |
| Alkem Lab | Pharmaceuticals | 4.75% |
| Cipla | Pharmaceuticals | 4.06% |
| Acutaas Chemical | Pharmaceuticals | 3.7% |
| Max Healthcare | Healthcare | 3.44% |
| Aster DM Quality | Healthcare | 3.37% |
| Lupin | Pharmaceuticals | 3.35% |
- 9.44%
Divi's Lab.
Pharmaceuticals
- 7.74%
Sun Pharma.Inds.
Pharmaceuticals
- 6.66%
Dr Reddy's Labs
Pharmaceuticals
- 5.19%
Apollo Hospitals
Healthcare
- 4.75%
Alkem Lab
Pharmaceuticals
Top Funds in the Category
| Fund Name | Rating | Category | 1Y | 3Y |
|---|---|---|---|---|
| — | Equity | 16.23% | 29.6% | |
| — | Equity | 28.41% | 28.89% | |
| — | Equity | 23.71% | 23.26% | |
| — | Equity | 20.06% | 21.85% | |
| — | Equity | 24.28% | 21.75% |
Peer Comparison
HDFC Pharma and Healthcare Fund - Regular (G)
- 1 Y Return
- 28.41%
- 3 Y Return
- 28.89%
- 5 Y Return
- —
Nifty 50
- 1 Y Return
- -2.32%
- 3 Y Return
- 9.41%
- 5 Y Return
- 8.00%
Investment Objective
To provide long-term capital appreciation by investing predominantly in equity and equity related s securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund Management

Nikhil Mathur
September 22, 2021 onwards HDFC Asset Management Company Limited July 26, 2017 to September 21, 2021 Ambit Capital India Pvt Ltd. Last Position Held: Vice President August 31, 2015 to July 25, 2017 Goldman Sachs (India) Securities Pvt Ltd. Last Position Held - Research Business Analyst September 8, 2014 to August 27, 2015 Deloitte Touche Tohmatsu India Private Ltd. Last Position Held - Assistant Manager June 17, 2013 to September 4, 2014 Ernst & Young LLP Last Position Held: Analyst
Riskometer
- Risk Score
- 6
- Risk Level
- Very High
Advanced Ratios
- AlphaReturn earned over the benchmark after adjusting for risk. Higher is better.
- 21.02
- BetaHow much the fund moves with the market. Above 1 means more volatile than the market.
- 0.66
- SRSharpe Ratio: return earned per unit of total risk taken. Higher is better.
- 1.31
- SDStandard Deviation: how much returns swing around their average. Lower means steadier returns.
- 16.11
- TRTreynor Ratio: return earned per unit of market risk (beta). Higher is better.
- 0.12
- P/EPrice to Earnings of the stocks the fund holds. Higher means a pricier portfolio.
- 59.66
Tax Implication
STCG Tax: 20% if redeemed before 1 Year. LTCG Tax: 12.5% exceeding Rs. 1,25,000/- post 1 Year
FAQs
HDFC Pharma and Healthcare Fund - Regular – Regular Plan - Growth was launched 3 years ago and has delivered annualised returns (CAGR) of 29.76% since inception. Here is how it compares with the category average:
Period Fund Category average 1 Year 28.41% 6.93% 3 Years 28.89% 14.57% Since Inception 29.76% Returns as on 18 Nov 2026. 1-year returns are absolute; returns above 1 year are CAGR. Past performance may or may not be sustained in future.
The expense ratio of HDFC Pharma and Healthcare Fund - Regular – Regular Plan - Growth is 2.12%. This is the annual fee for managing and operating the fund. It is adjusted in the daily NAV, so the returns you see are already net of this cost.
HDFC Pharma and Healthcare Fund - Regular is rated Very High risk on the SEBI riskometer. The riskometer has six levels, from Low to Very High, and fund houses review it every month.
You can start an SIP in HDFC Pharma and Healthcare Fund - Regular with ₹100 a month, or invest a lump sum of ₹100. Additional investments start at ₹100.
HDFC Pharma and Healthcare Fund - Regular charges an exit load of 1% if redeemed within 30 days of investment. The exit load is deducted from the redemption amount.
No, HDFC Pharma and Healthcare Fund - Regular has no lock-in period, so you can redeem anytime. An exit load may apply on early redemption.
HDFC Pharma and Healthcare Fund - Regular manages assets (AUM) of approximately ₹3,666 Cr.
As on 31 Oct 2026, HDFC Pharma and Healthcare Fund - Regular holds 40 securities. These are its top 10 holdings:
Company % of portfolio Divi's Lab. 9.44% Sun Pharma.Inds. 7.74% Dr Reddy's Labs 6.66% Apollo Hospitals 5.19% Alkem Lab 4.75% Cipla 4.06% Acutaas Chemical 3.70% Max Healthcare 3.44% Aster DM Quality 3.37% Lupin 3.35% As on 31 Oct 2026, these are the fund's largest sector allocations:
Sector % of portfolio Healthcare 98.79% Debt 1.21% If you invested through a Wealthy partner, you can place a redemption request in the Wealthy app, or ask your partner to do it for you. If you invested elsewhere, you can redeem through the HDFC Mutual Fund website, MF Central or CAMS. The money is credited to your registered bank account, usually within a few working days. Exit load and capital gains tax may apply.












